RWM
TGTX icon

Rialto Wealth Management’s TG Therapeutics TGTX Stock Holding History

Rialto Wealth Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$532 Buy
16
+12
+300% +$358 ﹤0.01% 1337
2025
Q4 		$120 Buy
+4
New +$131 ﹤0.01% 1608

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rialto Wealth Management's TGTX Position: Q1 2026 in Review

Rialto Wealth Management increased its TG Therapeutics (TGTX) stake by 300% in Q1 2026, buying an estimated $358 and bringing the position to 16 shares worth $532. The position accounts for ﹤0.01% of the portfolio, ranked #1337.

Rialto Wealth Management first reported a position in TGTX in Q4 2025 and has held it in 2 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Rialto Wealth Management held 16 shares of TG Therapeutics worth $532 as of Q1 2026.
  • Rialto Wealth Management bought 12 TG Therapeutics shares in Q1 2026, an estimated $358.
  • TG Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1337 holding.
  • Rialto Wealth Management first reported a position in TG Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.